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Abstract
Objectives: To determine the adjuvant effects of adenoidectomy with short-stay
ventilation tubes to hearing and revision surgery in children over 3.5 years with
persistent otitis media with effusion.
Design: Randomised controlled three armed trial: observation, short-stay ventilation
tube or ventilation tubes with adjuvant adenoidectomy. Five follow-up visits over 2
years.
Setting: Eleven UK Otorhinolaryngology Departments.
Participants: Children with bilateral otitis media with effusion and better ear hearing
level (HL) ‡20 dB persistent for 3 months. Of the 425 eligible children, 376 (88%)
accepted randomisation.
Main outcome measures: Pure-tone hearing thresholds, eligibility for and actual
revision surgery rates, otoscopic sequelae and complications of adenoidectomy.
Results: Loss to follow-up at 3, 12 and 24 months was 2%, 6% and 5% respectively.
Of the 376 randomised children, 253 (67%) had complete data for all five follow-up
visits. Adenoidectomy did not add to the benefit to hearing thresholds of ventilation
tubes of 8.8 dB (CI: 7.1–10.5) averaged over 3–6 months postoperatively. Averaged
over 12, 18 and 24 months, adenoidectomy provided 4.2 dB of benefit (CI: 2.6–5.7)
whilst ventilation tubes gave no benefit. Standardised effect sizes through two years
showed equal benefit from ventilation tubes (0.50 sd) and adenoidectomy (0.61 sd)
which are additive (1.11 sd). Adenoidectomy halved the numbers meeting a 25 dB
HL bilateral cut-off for eligibility for repeat tube surgery from 31% to 14% at 12
months and from 33% to 15% at 18 months. The actual reduction in re-insertion
surgery (absolute risk difference) was 21%. In tubed ears, tympanosclerosis
occurred in 27%, but otorrhoea in only <2% and permanent perforations in <1%.
These events did not occur in control ears. In children that had adenoidectomy, one
of 165 (0.6%) had haemorrhage that required return to theatre.
Conclusions: Adjuvant adenoidectomy doubles benefit from short-stay ventilation
tubes by extending better hearing through the second year in children aged 3.25–
6.75 years with persistent otitis media with effusion with at least a 20 dB HL in both
ears. The duration of benefit of adenoidectomy is related to the duration of function
of the type of the ventilation tubes used. Adenoidectomy also substantially reduces
eligibility for revision surgery.
Otitis media with effusion is the overriding cause of hearing loss in early and middle
childhood with high associated healthcare expenditure. The condition is largely self-
limiting, leading to much debate over justifications for surgery and to wide national
and international variation in intervention rates. Affected children may be surgically
treated by ventilation tube (VT) placement, also known as grommets or
tympanosotomy tubes, with or without adjuvant adenoidectomy (+ad).
The benefit from short-term VTs alone to hearing has been adequately shown in an
individual patient metaanalysis 1 and a Cochrane systematic review.2 Both of these
included raw data from the MRC funded Trial of Alternative Regimens in Glue Ear
Treatment (TARGET). However, the magnitude of the hearing benefit of VTs is small
and limited to the duration of tube patency.2 Hence, the NICE guideline3
recommended that only ‘children with persistent bilateral OME documented over a
period of 3 months with a hearing level (HL) in the better ear of 25–30 dB HL or
worse should be considered for surgical intervention’.
The adjuvant role of adenoidectomy to VTs was one of the main reasons why
TARGET was funded as previous adenoidectomy trials had conflicting evidence of
benefit to hearing and reduction in revision surgery rates.4,5 Because of the
inconsistent evidence, NICE restricted its recommendation of adenoidectomy to
children with co-present severe or persistent upper respiratory tract infection.
However, a recent trial has shown that these are themselves not indications for
adenoidectomy.6
This paper reports the adjuvant effects of adenoidectomy, along with short-stay VTs,
to hearing thresholds and revision surgery in children over 3.5 years with persistent
OME.
Methods
Recruitment took place between April 1994 and January 1998 in 11 UK ENT
departments (Fig. S1). Generalisability of the trial sample in relation to the referred
clinical caseload has been examined in some detail7 but the trial protocol is
summarised in the CONSORT flow diagram (Figs 1 and S1).
Eligibility criteria
Included children were aged 3¼–6¾ years on a first visit with no previous ear
surgery and had on two qualifying visits, three months apart: a bilateral B + B or B +
C2 tympanogram combination (modified Jerger),8 and better ear HL >= 20 dB HL
averaged across 0.5, 1, 2 and 4 kHz and air–bone gap > 10 dB.9 Non-independence
of these markers entails that the conjunction is not greatly more stringent than the 20
dB HL component alone.
At discretion of the consultant (Appendix S1), children with poorest HLs (binaural HL
> 40 dB HL) could be treated (i.e. not randomised) yet followed up. Another 42 also
with binaural HL > 40 dB HL remained in the randomised group and are included in
the intention-to-treat analysis.
All included children were followed up over five visits at 3, 6, 12, 18 and 24 months
post-randomisation.
Ethical considerations
The Trial was approved by the local research ethics committees for each centre as
well as the appropriate multicentre research ethics committees for England, Wales,
Scotland and N. Ireland.
Interventions
Eligible children with parental consent were randomised to one of three
interventions:
1 Bilateral Shepard VTs (http://www.invotec.net/ventilation_tubes.html) following
myringotomy and fluid aspiration (VTs).
2 Ventilation tubes with adjuvant adenoidectomy (VTs +ad).
3 Further watchful waiting (FWW).
All children receiving surgery received it within 6 weeks of randomisation and most
within 4 weeks, where different from allocation this was extracted from the surgical
notes.
Outcome measures
Hearing levels. Air conduction thresholds at 0.5, 1.0, 2.0 and 4.0 kHz in each ear at
every visit were summarised as the 4-frequency average binaural hearing thresholds
for comprehensiveness and reliability.9 To reliably adjust treatment arm comparisons
post-randomisation, the baseline HL was taken as the period average over the two
qualifying visits.
Revision surgery. If at any follow-up visit, the surgeon and the parent after perusing
the current hearing thresholds, tympanometry and otoscopy felt that revision surgery
was indicated and this was recorded. The type of revision surgery was later
documented and follow-up was as per protocol. No strict eligibility criterion was laid
down to allow surgeon ⁄ parent discretion, but the implication was that the children
should have bilateral OME with a hearing impairment of at least 20 dB HL in both
ears. Children that had revision surgery were analysed at the time intervals related to
their initial surgery.
Otoscopy. At each visit, the ears were examined by the consultant otologist using an
otoscope, supplemented by otomicroscopy where necessary. The findings
(discharge or other otoscopic suspicion of infection, perforation and
tympanosclerosis) were recorded on a summary data sheet with prompt categories
and schematic left and right eardrum diagrams (Appendix S1). The otoscopic
findings are reported on an ‘as treated’ basis and thus include children that
transferred to surgery from FWW.
Sample size. To address sustained benefits from adenoidectomy, a 3 dB difference
averaged over 12, 18 and 24 months was postulated as small yet worth knowing
about; this would capture the cumulative functional consequence of lesser disease
recurrence. Given the known variability of measurement, for alpha 0.01 with 80%
power, this needed equal group sizes of 110. Recruitment beyond this would assist
supplementary aims for interactions and for overall effects on other outcomes of
policy relevance, for which power calculation in advance was not feasible.
Randomisation. Randomisation was performed by telephone call from the nurse ⁄ 
research assistant to the statistician at the MRC Institute of Hearing Research and
allocation immediately communicated to the parent.
Sequence. For each centre, the first five children were randomised according to a
computer generated random number sequence. Thereafter, the minimisation
procedure 10 balanced the treatment allocations across four dichotomous factors:
boy, girl; £5.25, >5.25 years old at initial visit; manual, non-manual occupation of
head of household and baseline hearing £25 dB HL, >25 dB HL. This basis of
minimisation was not divulged to centres and may be regarded as completely
concealed. The process produced 122 (FWW), 126 (VTs) and 128 (VTs +ad) cases.
Blinding and bias. Audiometry was performed by audiologists, independently of the
otolaryngologist and research nurse. Clinic pressures meant that these testers,
whilst not blinded in the strictest sense, were not aware of the child’s allocation, nor
in a position to be influenced by such information were it present. True HLs are
unlikely to be affected by the parent’s or child’s knowledge of the intervention in a
surgical trial.
Statistical methods
Analysis strategy. All analyses were by-child and as-randomised (‘intention-to-treat’),
except where otherwise stated. We defined two natural summary periods for
outcome imputation: 3 plus 6 months when initial VTs are mostly still functioning, and
12, 18 and 24 months, when they are not.11
The appropriateness of this was confirmed by two non-imputed trajectories on cases
with all visits present by: (i) maximum cases, with the given variable present for the
particular visit, and (ii) complete cases, all having the given variable present at
baseline and every follow-up visit. For unbiased effect estimation, general linear
models (multiple regressions) predicted the continuous measures of outcomes from
two terms: the same variable at baseline (main-effect) and randomised treatment
allocation, a three-level categorical term. Further models including baseline
treatment interactions were also run, only briefly reported here. All models used
imputation for missing data on first, second or combined periods. Where necessary,
square root or logarithmic transformations were used to normalise residuals; as
these also homogenised variance, standardised treatment effect sizes (TES) used
SDs from pooled (three-arm) error estimates.
Results
Baseline characteristics and adherence to allocated management
Randomised group characteristics show no material or reliable difference, in any of
the demographic or traditional risk factor variables between groups (Table 1).
Over the 2-year follow-up period, 98 children (26%) transferred to a non-allocated
group (Fig. S1), mostly in the first year. The limited acceptability of FWW is shown by
69 (57%) children transferring from it to active treatment, with only 53 (43%) of FWW
not ultimately receiving surgery; the wider methodological implications of such high
transfer rates are considered more fully in a later paper. Among the 29 other
transfers, only three were from surgery to FWW, the majority (later) receiving
adjuvant adenoidectomy with re-insertion. As treated at 2 years, 53 had received
FWW, 146 VTs and 165 VTs +ad (Fig. S1). Loss to follow-up was no higher in the
FWW children (FWW 21; VTs 17, VTs +ad 20) suggesting that any transfer to
surgery outside the National Health Service was negligible if any.
Overall HL trajectory
The HL trajectories for complete data cases (N= 253) and for all cases seen at each
visit (Fig. 2) confirm effects of randomised VTs lasting less than one year for VTs,
but at least 2 years with additional adenoidectomy, hence the basis of analysis (and
imputation) in the two contrasting periods. At 1 year, most tubes (82%) are extruded
or non-functioning.11 Transfers eliminate any advantage for VTs thereafter but the
disadvantage (NS) seen is because of lag not harm. The HLs are then strikingly
stable, with the 12, 18 and 24 month means for FWW and VTs differing by only 0,
1.2 and 0.1 dB, respectively, and with VTs +ad consistently showing a 4 dB
advantage (Fig. 2 and Table S1).
Hearing level in early and late follow-up
Table 2 shows the HL for all randomised cases, aggregated for each follow-up
period. In the first 6 months, VTs confer large (TES = 1.28) and significant (P<
0.001) benefit to HL, but overall, adenoidectomy does not enhance this when the
VTs are mostly patent (i.e. treatment benefits appear subadditive). The 2nd year
imputed data show VT and FWW with similar HLs, but the +ad overall benefit is able
to emerge (P< 0.001), with +ad conferring a 4.2 dB (CI: 2.6–5.7 dB) benefit and no
significant diminution over time. Over the combined 2-year period, the advantage in
HL from +ad over VTs alone is also significant (P< 0.001). This longer duration of
adenoidectomy benefit makes the 2-year contributions of VTs and +ad to HL
complementary in time, and of broadly similar magnitude, (2-year TES = 0.50 sd for
VTs alone; 0.61 sd for +ad), consistent with the similar areas separating pairs of
lines in Fig. 2.
Indicator role for baseline severity
No significant correlation was found between the benefit to HL from VTs ±
adenoidectomy to the HL baseline.
Revision surgery and its relation to HLs
No formal criterion for revision surgery was imposed by the protocol, so the
essentially continuous HL data are reformulated as hypothetical eligibility criteria of
20, 25 or 30 dB HL (Table 3). Compared with the VT group, fewer children in the VTs
+ad group met these criteria in all analysis. At 3 months, no difference would be
expected, when most tubes were functioning. Over 12, 18 and 24 months, 35% (CI:
26–43) of 115 children in the VT group attending these visits versus 13% (CI: 7–19)
of 115 in VTs +ad group re-met a 25 dB HL cut-off, making children in the VTs alone
group more likely by about threefold (RR 2.7; CI: 1.6–4.6) to re-qualify for surgery
than those receiving VTs +ad.
Three months following randomisation, in 42% (CI: 33–51) of 106 children in the
non-surgical arm with data at this point, the OME had resolved sufficiently that they
no longer met the >=20 dB HL entry criterion. Imposing such dichotomous criteria
exaggerates short-term systematic (e.g. seasonal) and random fluctuation; only 47%
of these short-term resolvers (i.e. 21 children) then remained below 20 dB in at least
one ear through 2-year follow-up.
Through follow-up, clinicians had audiometric data available for clinical review and
re-insertion was discretionary; 78% of children then selected for reinsertion did in
fact re-meet the 20 dB HL trial entry criterion. Of the 126 randomised to VTs only, 38
(30%) received revision surgery, compared with 12 (9%) of the 128 children
randomised to VTs +ads (RR = 3.2; CI: 1.8–5.9). Of those who would have met a 25
dB better ear HL eligibility criterion in the second year of trial, 58% in the VTs group
versus 40% in the VTs +ad group underwent revision surgery (RR = 1.4; CI: 0.8–
2.4). Thus, HL was the main driver of repeat surgery and the contribution of
adenoidectomy to meeting HL cut-off largely explains its reduction of further surgery
– a different manifestation of the same outcome.
Adverse effects
Of 635 ears that had a VT inserted, eight had a perforation at visit 7 that was
recorded at least 6 months after any surgery. Subsequent record search showed that
in the four who attended a post visit 7 appointments, all had healed. Similarly, six of
seven perforations recorded at visits 5 or 6 and that could be checked at a
subsequent visits had resolved. Lasting perforations are therefore rare but at worst
there could be as many as 0.8% (5⁄635). Tympanosclerosis was seen in 20% (128 of 
635) ears versus none in un-operated ears. The incidence of infection associated
with VT insertion was low: only 43 ears (7%) showing it at any point over follow-up.
One of the 165 (0.6%) children that had adenoidectomy had to return to theatre for
postoperative haemorrhage. The trial was not designed to pick up other rare
complications of adenoidectomy including velo-pharyngeal incompetence.
Discussion
Synopsis of key findings
In children aged 3.25–6.75 years with persistent bilateral OME with a HL of at least
20 dB HL in both ears;
1. Where times are in common, TARGET results for VTs alone are similar to those
in other trials and meta-analyses.2 The average audiometric benefit to the
hearing thresholds from VTs of 8.8 dB re-controls (CI: 7.1–10.5) for the period
centred on 3–6 months post-randomisation disappeared by 12 months.
2. Adenoidectomy with VTs extends benefit to hearing through the second year
without evident diminution; the magnitude of this benefit was 4.2 dB HL (CI: 2.6–
5.7) over VTs alone. As a result in the combined operation, adenoidectomy
contributes approximately as much to hearing over 2 years as VTs do.
3. Adjuvant adenoidectomy reduces audiometric eligibility for revision surgery and
actual surgery rates; 34% of VTs group versus 13% of VTs +ad group met the 25
dB HL cut-off at some point over the second year of follow-up, giving an absolute
risk reduction of 21%.
Strengths of the study
TARGET is the only by-child RCT of VTs +ad in the age groups of 3.7–7 years
having bilateral persistent OME (i.e. with a HL of 20 dB or greater in both ears over 3
months). The children came from the NHS primary to secondary referral healthcare
system and were at the more severely affected end of the clinical distribution, after a
sixfold reduction of referrals by watchful waiting within the entry criteria.7 Second
year outcomes, particularly relevant to the contribution of adenoidectomy, were
thoroughly documented. The findings can thus be strongly generalised to selective
policies for secondary care case-loads in countries with restrictive prior referral and
similar entry criteria, but not to substantially younger or less selected caseloads.
For HL, complete data on all seven visits were available for 67% of children, on at
least one of the 3 and 6 months visits in 94%, and on at least one of the 12-, 18-,
and 24-month visits in 91%. The use of imputation adjusts for any attrition biases,
which were not removed in previous OME trials, but the degree of difference that this
can make was limited because of the reasonably high follow-up rate here and to
established absence of pointers to large bias such as particularly favourable or
unfavourable results just prior to missing data.
Limitations of the study
The follow-up schedule did not include 9 months, which could have given more
information on the emergence of an advantage for adenoidectomy, the duration of
VT benefits and optimum schedule for review on recurrence. It would also have been
beneficial to have had follow-up beyond 24 months to determine the duration of
additional benefit from adenoidectomy. Data on clinical reasons for re-insertions
supplementary to hearing could have documented practice and clinical belief,
perhaps suggesting supplementary indicators for interaction tests with hearing and
other outcomes.
The high proportion of cases transferring from further watchful waiting to surgical
management at 6 months will affect the overall hearing outcomes from surgery, on
an intention-to-treat analysis, but there is no reason to expect this to be different
between tubes alone and tubes with adenoidectomy. Hence, comparisons between
VTs alone and adenoidectomy in addition to tubes which are the novel aspect of this
paper are not likely to be influenced by transfers from the control arms to surgery.
Comparison with other studies
Three previous trials 4,12,13 randomised children to have or not have
adenoidectomy and one ear but not the other to have a VT inserted. Eligible children
were comparable to those in TARGET in age range, persistence of bilateral OME
with a defined >20 dB HL. Adenoidectomy had an additional benefit to hearing of 2
dB at 6 and 12 months.5
To date, the benefit in the second year after adenoidectomy has not been reported.
The current study shows the benefit of adenoidectomy in the second year to be of a
similar magnitude to hearing as VTs do in the first year.
Previous trials have shown a reduction in repeat operations of about a third of
children having adenoidectomy4 with varying degrees of OME. However, revision
surgery frequently takes place for multiple reasons, and the parents of many children
with persistent OME do not want their child to have a further operation. This study
overcomes these biases by reporting the audiometric eligibility for revision surgery at
various audiometric levels. The reduction achieved by adenoidectomy of 31–14% at
12 months and from 33% to 15% at 18 months using a 25 dB HL cut-off is chosen as
that is the level in the current NICE guidelines.3
Tympanosclerosis and otorrhoea are well-recognised sequelae of VTs, and
TARGET’s prevalence of these is in keeping with meta-analysis by Kay et al.15
However, the ‘maximum’ incidence of chronic perforation of 0.8% is lower than Kay
et al.’s figure of 2.2% (CI: 1.8–5.0) for short-term tubes. The most likely reason for
this is that the incidence of otorrhoea in TARGET was low because OME rather than
recurrent acute otitis media was the rational for tympanostomy. A less likely
alternative is a difference in VT design or material.
Policy implications
In children with relatively severe and persistent bilateral OME distribution, there is a
significant benefit of about 9 dB from short-stay VTs alone, when averaged over 3
and 6 months. At 1 standard deviation of the outcome measure distribution, this
meets the general criterion for a statistically large effect, and a similar magnitude is
seen through 2 years if adjuvant adenoidectomy is also performed. The result need
not be seen as surprising when prior selection by the entry criteria removes the non-
persistent five sixths of the referred caseload. The trade-off between benefits and
risks or side-effects, comparing longer-stay tubes with adjuvant adenoidectomy, is
certainly complex and has never been comprehensively addressed. What is lacking
is quality information of duration of tube function for alternative tubes.14 Other types
of tubes were to function for a longer period of time that might lessen the proportion
of time in the second year that a child would benefit from adenoidectomy. However,
the majority of children do not need their middle ear ventilated for longer than with a
Shepard tube. For them, longer-stay tubes would be both unnecessary and result in
more frequent sequelae.
Showing advantage for one strategy does not remove the need to consider the other,
but if adenoidectomy is shown to benefit general health in OME, the attractiveness of
longer-stay tubes would be less.
The extension of hearing improvement with adenoidectomy and the reduced number
of children receiving repeat surgery appear closely related. The absolute risk
reduction of re-insertion by 21% is substantial for the case type entering and can be
set against the increased risk of adenoidectomy. A 100% adjuvant adenoidectomy
rate in persistent OME is not appropriate on grounds of logistics (scheduling of
operating list) or the risk of haemorrhage, even if offset by the reduced risk of re-
insertion, so cost-effectiveness analysis on the entire VTs +ad arm would be too
crude to be informative. The concentration of the present average benefits into
definable subgroups for the respective treatment components therefore has high
priority. Recommendations on surgery in children over three and a half years should
address the joint and complementary deployment of the two operations, and routine
hospital activity data should henceforth distinguish this definite adjuvant role in OME
from other reasons for adenoidectomy in children.
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Fig. 1. Consort diagram showing pathway of the children through the 3-month
qualifying period (three visits) and the 24-month follow-up period (five visits).
Table 1: Baseline characteristics of 376 randomised children.
Further watchful
waiting N = 122 VTs N=126 VTs +ad N=128 Total N=376 Missing % P-value
Age at randomisation in months
Mean (sd) 62.9 (10.4) 62.5 (10.2) 64.5 (10.3) 63.3 (10.3) 0 0.27
Gender %
Male 51 48 48 49 0 0.91
Socio-economic group %
Manual 67 67 65 66
N 122 126 125 373 0.8 0.92
Ethnic group %
White 96 98 95 96
Afro-Carib 1
Indian-Pakistani 3 2 3 3
Other 1 1 1
N 122 126 125 373 0.8 0.78
Season when randomised
Winter (January–March) 36 26 28 30
Spring (April–June) 27 33 35 32
Summer (July–Sept.) 20 26 18 21
Autumn (October–Dec.) 17 14 19 17
N 122 126 128 376 0 0.35
Mean hearing level dB HL (sd)
Visit 2 33.5 (6.4) 32.2 (6.0) 31.7 (6.4) 32.4 (6.3) 0 0.07
Av visits 1 and 2 33.8 (4.8) 33.2 (4.6) 32.8 (5.2) 33.2 (4.9) 0 0.24
Mean reported hearing difficulty – RHD (sd)
Visit 2 13.6 (4.5) 14.4 (4.1) 14.0 (4.2) 14.1 (4.3)
N 110 122 120 352 6.4 0.63
Av visits 1 and 2 13.2 (4.1) 13.9 (3.8) 13.6 (3.8) 13.5 (3.9)
N 122 126 127 375 0.3 0.39
Other siblings with OM
Yes 83 83 88 84
N 122 126 127 375 0.5 0.39
Acute otitis media episodes %
> 6 per year 7 4 4 5
N 122 126 127 375 5.6 0.54
Attended daycare %
Yes 100 98 100 99
N 110 123 120 353 6.1 0.06†
Mother smokes %
Yes 29 32 40 34
N 101 110 115 326 13.3 0.19
† Low numbers not attending daycare suggest the marginally significant result is unreliable.
Fig. 2. Time course of hearing level (HL). Mean HL and 95% CIs of the HL scores for complete data (n = 253) are compared with
those for maximum data available in the 376 randomised children.
Table 2. Descriptives and standardised treatment effect sizes (TES) in sd for hearing levels (HL), for the two follow-up periods and
combined, and TESs for the same contrasted between measures. The two treatment groups are each specified relative to further
watchful waiting (FWW) controls
HL Mean sd CI TES*
3 and 6month visit average
VTs 15.9 6.2 14.8, 17.0 1.28
VTs +ad 14.6 6.1 13.6, 15.7 1.50
FWW Ctrls 24.7 7.7 23.3, 26.1 Difference 0.23†
12, 18, 24 months visit average
VTs 20.1 6.5 19.0, 21.2 -0.14‡
VTs +ad 15.9 5.9 14.9, 17.0 0.55
FWW Ctrls 19.4 6.2 18.3, 20.5 Difference 0.69
2-year combined period average§
VTs 18.5 5.2 17.6, 19.5 0.50
VTs +ad 15.5 5.3 14.5, 16.4 1.11
FWW Ctrls 21.4 5.6 20.4, 22.4 Difference 0.61
Values are imputed for missing data, giving complete as randomised Ns of 122, 126 and 128, respectively, for FWW, VTs and VTs
+ad. The means, SDs, CIs given here are raw but the TESs are based on distributions transformed to normality as for statistical
tests. The TES for a sum or difference is close to, but cannot be precisely deduced from, those entailed by its parts; this is because
of correlation affecting the variance for the sum or difference.
* Standardised treatment effect size. This is the ratio of the mean difference between the two treatment groups in question to the
pooled sd in the as-randomised analyses.
† This and all other italicised entries are not for FWW, but for the differences in TES of the two treatment regimens in rows above.
‡ Negative value (NS) occurs because in this period more of the control group have transferred to treatment, and so have
functioning VTs, than is seen in the surgery groups where VTs have mostly fallen out.
§ Weighted as 9 : 15 for the numbers of months in which the follow-up visits are centred, with 3 months’ margin at boundary, e.g. 3-
and 6-month measures centre on 0–9 months.
Table 3. Eligibility rates for revision surgery as defined for 20, 25 and 30 dB cut-offs in HL, for the 254 children randomised to
surgery in TARGET
Allocated % with % with % with Fisher exact test
Visit group HL>20 dB HL>25 dB HL>30 dB N for HL >25 dB P-value Relative risk
3 Vts 7 4 2 109 >0.1
Vts +ads 8 3 2 116
4 Vts 18 8 7 111 >0.1
Vts +ads 10 7 3 114
5 Vts 31 16 10 110 0.039 2.3
Vts +ads 14 7 4 111
6 Vts 33 18 13 103 0.001 4.8
Vts +ads 15 4 2 103
7 Vts 26 15 6 108 0.026 2.7
Vts +ads 17 6 1 109
Any of 5,6,7 Vts 61 40 26 115 <0.001 2.7
Vts +ads 37 15 7 115
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Figure S1.
Fuller CONSORT diagram for TARGET study.
Table S1.
Mean HL (standard deviation) at baseline and at each visit up to end of 2-year
follow-up.
Appendix S1.
Otomicroscopy Coding Form.
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Web appendices
Figure S1. Fuller CONSORT diagram
Appendix S1. Otomicroscopy coding form
Table S1. Mean HL (standard deviation) at baseline and at each visit to end of 2-
year follow-up. Data are presented for (i) maximum number of cases available and
(ii) for cases having complete data across all visits. HL data are displayed in Figure
2.
Figure S1: Fuller CONSORT diagram for TARGET study
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3 Discontinued centres
n = 471
Randomised
n = 376
Transfers:
•VTs → VTs+Ad: n=2
•VTs → VTs: n=1 (1st → FWW)
LTFU : n = 0, 1, 4, 2
(above order)
Transfers:
•VTs → VTs+Ad+T: n=1
LTFU : n = 1, 1, 1, 1
(above order)
Transfers to:
•FWW: n = 3 (incl. 2 later → VTs)
•VTs: n= 4
LTFU : n=6 (incl. 2 transfers)
Transfers to:
•FWW: n = 4 (2 later →VT→VTs+Ad)
•VTs+Ad: n=1
•EAU: n=1
LTFU : n=4
Transfers to:
•VT: n= 2 (both 2nd transfers from
FWW; 1 later →VTs+Ad)
LTFU : n=8
Transfers to:
•VTs+Ad: n=1
•VTs+Ad + T: n=1
Return to VTs: n=1 (later →VTs+Ad)
LTFU : n=7
Transfers to:
•VT: n=22 (2 later → VTs+Ad) 
•VTs+Ad: n=18
•VTs+Ad+T:n=1
LTFU : n=8 (incl. 7 transfers)
Transfers to:
•VTs+Ad+T: n=1
Return to VTs+Ad: n=1
LTFU : n=6
Transfers to:
• VTs+Ad: n=11 (2 FWW→VT→VTs+Ad )
•VT + T: n=1;
•VT + Ads + T: n=2
LTFU : n=6
Transfers to:
•VT: n=12
•VTs+Ad: n=6 (incl. 2 from VTs)
•EAU: n=1
LTFU : n=6 (incl.2 transfers)
Remained as FWW
n = 53 (69) [21]
Received VTs only
n = 105 (21) [17]
Received VTs+Ad
n = 121 (7) [20]
Received VTs only
n = 18 (2) [8]
Received VTs+Ad
n = 22 (0) [8]
Transfers:
•VTs → FWW: n=1 
•VTs+Ad→FWW: n=1 [later→VTs]
LTFU : n = 0, 1, 2, 1
(above order – incl 2 transfers)
Transfers to:
•VT: n = 4
•VTs+Ad: n= 8
LTFU: n=7 (incl. 1 transfer)
S1: Fuller CONSORT diagram for TARGET study
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Notes to support interpretation of CONSORT diagram
1. Abbreviations: FWW = Forward watchful waiting ie non-surgical controls;
VTs= Ventilation Tubes (aka grommets, tympanostomy tubes, pressure equalisation tubes (PETs));
VTs+Ad= Ventilation Tubes plus Adenoidectomy;
LTFU = Lost to follow up (children not completing their 2-year follow-up).
2. Exclusions (green box)
2.1.Overriding Concern: Where consultant or parent was unduly concerned over a child’s speech/language, behaviour, otalgia
or nose/throat problems, the child could be managed outside TARGET. Such children differed in the expected ways4 from
included children and in total at visits 1 and 2 represent only 9.8% of children with a confirmed condition at Visit 1.
2.2. Visit 1 and Visit 2 audiometric inclusion criteria were: better ear HL≥20 dB, air-bone gap >10 dB and binaural tympanogram 
combination of (B, B) or (B, C2).
2.3. “Other” exclusions include previous VT/ad surgery, outside age limits, not accompanied by parent/guardian, other medical
exclusion, significant family language problems, parent refusing to take part in study, child unable/unwilling to do
audiometry, administrative problems, family/social reasons and protocol mishaps, particularly early in the trial.
3. Discontinued centres (grey box)
3 centres were unable to continue recruiting for TARGET. Children from these centres are excluded from the main TARGET
outcomes analyses as they were unable to complete follow up when their centres discontinued TARGET work.
4. Children with HL>40 dB (blue boxes).
Children with binaural average HL > 40 dB on either qualifying visit were given the option of immediate non-randomised listing
for surgery, either VTs or VTs+ad, at the consultant’s discretion. All 56 children so listed for surgery were followed within
TARGET for 2 years. One child included in this group did not strictly meet the criteria with binaural average HL=40 dB.
5. Eligible children (pink box)
A total of 441 children met the eligibility criteria on both qualifying visits. Of these 16 joined the HL>40 dB program. The
remaining were offered entry into TARGET and 49 of these refused randomisation.
6. Children allocated a treatment plan and entered for full 2-ear follow-up (purple box)
The 376 randomised (yellow boxes) and 56 HL>40 dB children (blue boxes) gave 432 children on whom 2-year follow-up data
was collected.
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7. Children transferring from allocated treatment continued to be followed for 2-years under TARGET.
8. Data for the 74 follow-up cases were imputed to retain 376 randomised and 56 HL>40 dB cases for analyses. Their final
treatment is listed as that recorded at their final attended visit.
26
Appendix S1: Otomicroscopy Coding Form
(You may wish to use hospital labels for patient details) CONFIDENTIAL
Child's name:
Date of birth:
Hospital number:
Address:
Date: Otologist
:
Instrument used
(Please
circle)
Otoscope/Otomicrosc
ope
Right Left
Middle Ear Fluid 0 / ? / + / TM not seen (9)
Pars Tensa A B C A B C
Ventilation tube 0-4
Chalk patch 0 / ? / +
Tympanosclerotic
plaque
0 / ? / +
Perforation none (0) / inactive (+) / active (++) / not sure
(?)
Retraction Sadé 0-4
Pars Flaccida Right Left
Attic retraction Tos 0-5
Comments: RIGHT TM LEFT TM
Otomicroscopy Coding Form ³
(Office use)
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Key to coding scheme
Retraction (Sadé) Ventilation tube
0: no retraction 0 N/A
1: slight retraction 1 functioning
2: retraction of TM touching incus or stapes 2 extruded
3: TM touching promontorium 3 blocked
4: adhesive otitis media 4 infected
Attic retraction (Tos) (See diagrams below)
0: no attic retraction
1: retraction towards neck of malleus, air space visible
2: retraction beyond osseous annulus, bottom of retraction visible
when head is tilted; may be slight bone resorption
3: distinct bone resorption of osseous annulus, retraction to head
of malleus
4: attic cholesteatoma
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Table S1: Mean HL (standard deviation) at baseline and at each visit up to
end of 2-year follow-up. Data are presented for (i) maximum number of
cases available and (ii) for cases having complete data across all visits.
HL data are displayed in Figure 2.
a) HL data
i. Maximum number of cases available at each visit
FWW VTs VTs+ad Total
Mean HL
(SD)
N Mean HL
(SD)
N Mean HL
(SD)
N Mean HL
(SD)
N
Baseline
(ave visits 1 and 2) 33.8 (4.8) 122 33.2 (4.6) 126 32.8 (5.2) 128 33.2 (4.9) 376
Visit 3
(+3 months)
26.3 (9.9) 106 14.4 (6.9) 109 13.6 (6.0) 116 17.9 (9.6) 331
Visit 4
(+6 months) 23.1 (10.1) 105 17.5 (8.2) 106 15.4 (8.1) 112 18.6 (9.4) 323
Visit 5
(+12 months)
20. 5 (10.1) 100 21.0 (9.4) 110 17.1 (9.1) 111 19.5 (9.7) 321
Visit 6
(+18 months) 19.7 (10.4) 98 21.1 (10.2) 103 15.7 (7.3) 103 18.8 (9.6) 304
Visit 7
(+24 months)
18.2 (8.1) 102 18.7 (8.9) 108 14.8 (7.7) 109 17.2 (8.4) 319
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a) HL data
ii. Cases with complete data at all visits
FWW VTs VTs+ad Total
Mean HL
(SD)
N Mean HL
(SD)
N Mean HL
(SD)
N Mean HL
(SD)
N
Baseline
(ave visits 1 and 2) 34.5 (4.7)
76
33.6 (4.6)
85
32.8 (4.9)
92
33.6 (4.8)
253
Visit 3
(+3 months)
26.3 (10.3) 14.4 (6.8) 13.8 (6.4) 17.8 (9.6)
Visit 4
(+6 months) 23.9 (10.7) 18.2 (8.7) 15.2 (7.3) 18.8 (9.5)
Visit 5
(+12 months)
20.4 (9.9) 20.4 (9.1) 16.5 (8.0) 19.0 (9.1)
Visit 6
(+18 months) 20.3 (10.3) 21.5 (10.3) 15.6 (7.2) 19.0 (9.6)
Visit 7
(+24 months)
18.3 (8.2) 18.4 (8.6) 14.8 (7.7) 17.1 (8.3)
